BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 23450347)

  • 1. Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus.
    Urbonaviciute V; Starke C; Pirschel W; Pohle S; Frey S; Daniel C; Amann K; Schett G; Herrmann M; Voll RE
    Arthritis Rheum; 2013 Jun; 65(6):1612-23. PubMed ID: 23450347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis.
    Savarese E; Steinberg C; Pawar RD; Reindl W; Akira S; Anders HJ; Krug A
    Arthritis Rheum; 2008 Apr; 58(4):1107-15. PubMed ID: 18383384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy.
    Summers SA; Hoi A; Steinmetz OM; O'Sullivan KM; Ooi JD; Odobasic D; Akira S; Kitching AR; Holdsworth SR
    J Autoimmun; 2010 Dec; 35(4):291-8. PubMed ID: 20810248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies to ribosomal P antigens with immune complex glomerulonephritis in SJL mice treated with pristane.
    Satoh M; Hamilton KJ; Ajmani AK; Dong X; Wang J; Kanwar YS; Reeves WH
    J Immunol; 1996 Oct; 157(7):3200-6. PubMed ID: 8816434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors.
    Clynes R; Calvani N; Croker BP; Richards HB
    Clin Exp Immunol; 2005 Aug; 141(2):230-7. PubMed ID: 15996187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus.
    Urbonaviciute V; Voll RE
    J Intern Med; 2011 Oct; 270(4):309-18. PubMed ID: 21793951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice.
    Richards HB; Satoh M; Jennette JC; Okano T; Kanwar YS; Reeves WH
    Clin Exp Immunol; 1999 Mar; 115(3):547-53. PubMed ID: 10193432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephritogenic autoantibodies but absence of nephritis in Il-12p35-deficient mice with pristane-induced lupus.
    Calvani N; Satoh M; Croker BP; Reeves WH; Richards HB
    Kidney Int; 2003 Sep; 64(3):897-905. PubMed ID: 12911539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance of autoantibody production in pristane-induced murine lupus.
    Han S; Zhuang H; Xu Y; Lee P; Li Y; Wilson JC; Vidal O; Choi HS; Sun Y; Yang LJ; Reeves WH
    Arthritis Res Ther; 2015 Dec; 17():384. PubMed ID: 26717913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-17 promotes murine lupus.
    Amarilyo G; Lourenço EV; Shi FD; La Cava A
    J Immunol; 2014 Jul; 193(2):540-3. PubMed ID: 24920843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. X-linked immunodeficient mice spontaneously produce lupus-related anti-RNA helicase A autoantibodies, but are resistant to pristane-induced lupus.
    Satoh M; Mizutani A; Behney KM; Kuroda Y; Akaogi J; Yoshida H; Nacionales DC; Hirakata M; Ono N; Reeves WH
    Int Immunol; 2003 Sep; 15(9):1117-24. PubMed ID: 12917264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Lgals9 Deficiency in Attenuating Nephritis and Arthritis in BALB/c Mice in a Pristane-Induced Lupus Model.
    Zeggar S; Watanabe KS; Teshigawara S; Hiramatsu S; Katsuyama T; Katsuyama E; Watanabe H; Matsumoto Y; Kawabata T; Sada KE; Niki T; Hirashima M; Wada J
    Arthritis Rheumatol; 2018 Jul; 70(7):1089-1101. PubMed ID: 29481735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis.
    Enghard P; Langnickel D; Riemekasten G
    Scand J Rheumatol; 2006; 35(3):209-16. PubMed ID: 16766368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of SIGIRR/TIR8 aggravates hydrocarbon oil-induced lupus nephritis.
    Lech M; Skuginna V; Kulkarni OP; Gong J; Wei T; Stark RW; Garlanda C; Mantovani A; Anders HJ
    J Pathol; 2010 Apr; 220(5):596-607. PubMed ID: 20112371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane.
    Summers SA; Odobasic D; Khouri MB; Steinmetz OM; Yang Y; Holdsworth SR; Kitching AR
    Clin Exp Immunol; 2014 Jun; 176(3):341-50. PubMed ID: 24528105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fas and Fas ligand mutations inhibit autoantibody production in pristane-induced lupus.
    Satoh M; Weintraub JP; Yoshida H; Shaheen VM; Richards HB; Shaw M; Reeves WH
    J Immunol; 2000 Jul; 165(2):1036-43. PubMed ID: 10878381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus.
    Richards HB; Satoh M; Shaw M; Libert C; Poli V; Reeves WH
    J Exp Med; 1998 Sep; 188(5):985-90. PubMed ID: 9730900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus.
    Thibault DL; Graham KL; Lee LY; Balboni I; Hertzog PJ; Utz PJ
    Arthritis Res Ther; 2009; 11(4):R112. PubMed ID: 19624844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus.
    Lartigue A; Colliou N; Calbo S; François A; Jacquot S; Arnoult C; Tron F; Gilbert D; Musette P
    J Immunol; 2009 Nov; 183(10):6207-16. PubMed ID: 19841185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TLR9 Deficiency Leads to Accelerated Renal Disease and Myeloid Lineage Abnormalities in Pristane-Induced Murine Lupus.
    Bossaller L; Christ A; Pelka K; Nündel K; Chiang PI; Pang C; Mishra N; Busto P; Bonegio RG; Schmidt RE; Latz E; Marshak-Rothstein A
    J Immunol; 2016 Aug; 197(4):1044-53. PubMed ID: 27354219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.